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Background: Fluorodeoxyglucose-positron emission tomography
(FDG-PET) has proven its value in the diagnosis of undetermined
pulmonary lesions, lung cancer staging, and assessment of progno-
sis. Purpose of this study is to clarify whether standardized uptake
value (SUV) can predict clinical outcome of computed tomography
(CT) screening detected lung cancer.
Methods: We tested the predictive value of FDG-PET using SUV
on long-term survival of 34 lung cancer patients, detected from 1035
heavy smokers 50 years monitored by annual low-dose CT for 5
years, with a median follow-up of 75 months from diagnosis.
Findings: PET scan was performed in 34 (89%) of 38 lung cancer
patients diagnosed during the 5 years of screening and was positive
in 32 (94%). Complete resection was achieved in 30 cases (88%), 20
(59%) were pathologic stage I and 23 (68%) were adenocarcinoma.
Median SUV was 5.0 overall, being significantly lower in stage I
(2.5 vs. 10.1, p  0.001) and in adenocarcinoma (2.5 vs. 13.0, p 
0.001). The 5-year survival of lung cancer patients was 100% for
SUV levels 2.5, 60% for SUV more than 2.5 and less than 8, and
only 20% for SUV 8 (p  0.001).
Conclusions: FDG-PET using SUV can predict long-term survival
of screening detected lung cancer, in a noninvasive manner. Meta-
bolic assessment of biologic behavior might improve the clinical
management of CT-detected lung cancer and reduce the risk of
unnecessary treatments for indolent disease.
Key Words: FDG-PET, Lung cancer screening, Standardized up-
take value.
(J Thorac Oncol. 2009;4: 1352–1356)
Lung cancer causes over 1.3 millions annual deaths world-wide.1 The overall survival of all detected lung cancers is
15% in the United States and 10% in Europe.2,3
In the last decade, nonrandomized trials on spiral com-
puted tomography (CT) screening have provided conflicting
results, where the higher proportion of CT detected stage I
lung cancer and 90% estimated long-term survival,4 was
counterbalanced by a more than threefold excess of lung
cancer diagnosis and no reduction of expected mortality at 5
years,5 highlighting the risk of overdiagnosis and ineffective
early treatment, already shown by the National Cancer Insti-
tute trials with chest radiography.6
Although the results of on-going randomized trial on
CT screening mature, it is important to expand our knowl-
edge on the biology of screening detected lung cancers
through pilot CT trials.
Among the various biologic parameters tested in lung
cancer patients, the concentration of fluorodeoxyglucose (FDG)
metabolic activity, quantitatively expressed by standardized up-
take value (SUV), seemed very promising for its ability to
predict lung cancer prognosis and potentially modulate treat-
ment, in a noninvasive manner.7,8 This study was started in
Milan in 2000 on 1035 heavy smokers and was the first screen-
ing experience to apply systematic use of positron emission
tomography (PET) in the diagnostic algorithm of spiral CT, as a
replacement of needle-aspiration biopsy for lesions 7 mm.9
In our lung cancer screening trial, we added PET imaging
in an attempt to identify subjects who required further evaluation
and eliminate unnecessary testing of benign pulmonary lesions.
Furthermore, we aimed at better understanding of the biology of
screening detected lung cancers and predicting long-term sur-
vival in a noninvasive manner.
This study evaluates the correlation between SUV and
clinical features of screening detected lung cancers and the
impact of SUV on patient’s survival.
MATERIALS AND METHODS
Between June 2000 and June 2001, 1035 current or
former smokers, 50 years of age, with 20 pack-years of
smoking history, no prior malignant disease, and adequate
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performance status to tolerate pulmonary resection were re-
cruited in this study.9 Informed consent included written
agreement to accept annual spiral CT for 5 years, blood and
sputum sampling, an epidemiologic questionnaire, and basic
spirometry. Median age was 58 years (range 50– 84), 739
subjects (71%) were men, average tobacco consumption was
26 cigarettes per day for 37 years (median pack-years  40),
and 14% had stopped smoking before accrual.
During the 5 years of screening, a total of 4832 annual
CTs have been performed; final compliance at 5th year was
86%, and cumulative recall rate 19%. Lung cancer was
diagnosed in 38 cases, 11 at baseline and 27 from 2nd to 5th
year, corresponding to 3.7% of enrolled and 20% of recalled
subjects. This number includes one case of interval cancer at
4th year.
Baseline and annual single-slice spiral CT was per-
formed without contrast material, with a low-dose protocol
140 kVp and 40 mA; pitch 2; 10 mm collimation; single
breath; and reconstruction with lung algorithm at 5-mm
interval (General Electric CT Hispeed, 1998). Effective radi-
ation dose was equivalent to 0.7 mSv (0.014 mSv
mGy1cm1 50 mGy cm). Calcified nodules or lesions5
mm were scheduled for repeat low-dose CT at 1 year.
Noncalcified lesions greater than 5 mm were further evalu-
ated by high-resolution contrast CT, with thin-sections (140
kVp and 220 mA; pitch 1; 1 mm collimation) and assessment
of contrast enhancement within 3 months of baseline CT.
All patients with nodules of 7 mm or greater underwent
a PET-FDG study. In particular, each patient received an
intravenous injection of about 100 Ci/kg body weight (3.7
MBq/kg body weight) of FDG in fasting condition for at least
6 hours. At the time of tracer injection, glucose blood level
was measured and only patients with glycemia less than 180
mg/dl were injected. One hour after injection, each patient
was positioned supine on the tomographic bed with arms over
the head, and a whole-body emission scan (5 minutes per bed
position) was started covering a field of view from neck to
pelvis. Imaging data were acquired with a GE Advance PET
scanner (General Electric Medical Systems, Milwaukee, WI;
axial field of view of 15 cm and spatial resolution of approx-
imately 5 mm). Transmission scan (3 minutes per bed posi-
tion) was then performed on thorax region to measure atten-
uation. Raw data were corrected for measured attenuation
using segmented transmission data and then reconstructed in
transaxial images using an iterative algorithm with 16 subset
and order 4. No correction for partial-volume effect was
performed. Parametric SUV transaxial images were obtained
normalizing each pixel for injected dose and body weight as
follows: SUV  (pixel-by-pixel activity in Bq/ml)/(injected
dose in MBq/body weight in kg). Circular regions of interest
were manually drawn on transaxial images around the FDG-
uptake area, and the maximum SUV was calculated to min-
imize the partial volume effect. The regions of interest with
the maximum value of SUV of different slices of each nodule
was considered for statistical analysis, and throughout the
study SUV is equivalent to SUVmax. Lesions with positive
FDG uptake (SUV 2.0) were candidates for biopsy.
Cutoff values for SUV analysis were selected to obtain
the best discriminatory power in terms of clinical features
(stage and histology) and outcome, with the specific aim of
identifying slow-growing tumors and highly metastatic can-
cers on the basis of metabolic profile.
Survival curves were computed with the Kaplan-Meier
method and compared with the log rank test. Statistical
analyses were carried out using SAS. Two-sided p values
below 0.05 were considered statistically significant. Median
follow-up of lung cancer patients was 75 months.
The study protocol followed internal review board
principles and was approved by the Ethics Committee.
RESULTS
PET scan was performed in 68 subjects (1.4% of all
CTs, 35% of recalled individuals), and in 34 (89%) of the 38
lung cancer patients, being positive in 32 (94%) of them.
Adenocarcinoma was the most frequent histology, with 23 cases
(68%); other types included six squamous, three small cell, and
two large cell carcinomas. Pathologic stage was the following:
18 Ia, 2 Ib (stage I 59%), 3 IIb, 7 IIIa, 2 IIIb, and 2 IV. Complete
resection was achieved in 30 of 34 cases (88%).
Four CT-detected cancers could not be assessed by PET
because of inadequate blood sugar control or claustrophobia.
True-negative studies were 28. Two false-negative cases
occurred in well-differentiated adenocarcinomas (8 and 11
mm of size) with significant bronchioloalveolar carcinoma
(BAC) component. Three false-positive cases occurred at
baseline (bronchiectasis, pulmonary sclerosis with lympho-
cytic infiltrates, and inflammatory pseudotumor), and three
cases in the following 4 years (two nonnecrotising granulo-
matosis and one organized bronchiolitis obliterans). Overall
diagnostic sensitivity of PET was 94%, specificity 82%,
accuracy 88%, positive predictive value 84%, and negative
predictive value 93%.
Table 1 shows the intensity of SUV by clinical features
of lung cancer patients. Based on SUV distribution, the
population was divided in three different SUV groups: lower
level 2.5, medium level more than 2.5 and less than 8,
higher level 8.
Median SUV was 5.0 overall, being significantly lower
in stage I than in stage II–IV (2.5 vs. 10.1, p  0.001). A
further decrease of was observed in the subset of stage I 15
mm of diameter, where median SUV was 2.0. A similar
difference was observed for histology, where adenocarcino-
mas showed a significantly lower SUV than the other cell
types (2.9 vs. 10.1, p  0.001).
TABLE 1. Results of PET
SUV
<2.5 >2.5, <8 >8 Median
All cancers 10 11 13 5.0
Stage I 10 (100%) 8 (73%) 2 (15%) 2.5
Stage II–IV 0 (0%) 3 (27%) 11 (85%) 10.1
Adenocarcinoma 9 (90%) 7 (64%) 6 (46%) 2.9
Other types 1 (10%) 4 (36%) 7 (54%) 10.1
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Interestingly, all cases with SUV2.5 were stage I and
90% adenocarcinomas. Among them, none was a pure
(100%) BAC but the majority showed a mixed pattern with
significant (30–90%) BAC component. However, only half
of stage I tumors had a SUV 2.5. On the contrary, 85% of
patients in the higher group (SUV 8) were advanced stages
and 54% other types than adenocarcinoma.
Figure 1 shows the long-term survival according to SUV
levels. With a median follow-up of 75 months, 5-year survival
was 100% for SUV levels 2.5, 60% for SUV more than 2.5
and less than 8, and only 20% for SUVmax 8 (p  0.001).
DISCUSSION
The clinical value of FDG-PET in the differential
diagnosis of undetermined pulmonary nodules detected by
spiral CT has been confirmed by several meta-analyses,
showing a sensitivity of 96 to 97% and a specificity of 78 to
82%,10,11 with the accuracy reaching 92% with PET tomo-
graphs12 and 93% with PET-CT integrated tomographs.13 The
benefit of PET staging has been advocated by several retro-
spective studies, showing high accuracy in the characteriza-
tion of multiple pulmonary lesions14,15 and detection of re-
gional and distant metastases;16–18 however, the randomized
PLUS trial provided definitive evidence that preoperative
PET prevented useless surgery in over 20% of deemed
resectable patients.19 Nonetheless, PET imaging is not a
replacement for pathologic staging. Nonetheless, PET imag-
ing is not a replacement for pathologic staging and tissue
biopsy of positive sites is often required to modify patients
management.
In our study, PET has proved effective in the manage-
ment of nodules 7 mm, to avoid complex needle-aspiration
biopsies and achieve final diagnosis in less than 3 months.
The 5-year results of our CT screening program are consistent
with those observed in the Mayo CT trial,20 with a cumulative
lung cancer detection rate of 3.7% (0.7% per year), a resect-
ability rate of 87%, and a proportion of stage I disease of
63%, and confirm the validity of a diagnostic algorithm that
considered nonsuspicious all lesions with maximum diameter
of 5 mm.
At the end of 5th year, PET had been applied only to a
small minority (1.4%) of all low-dose spiral CTs, with diag-
nostic accuracy of 86% at baseline and 90% thereafter, with
high sensitivity (94%) and negative predictive value (93%).
As expected, main limiting factors in early detection were
false-positive findings because of inflammatory lesions and
false-negative findings because of small size adenocarcino-
mas with predominant BAC component.21–24 However, the
apparent diagnostic failure of PET in small cancers, with
predominant BAC features,24 may turn positive when quan-
tification through SUV is performed with prognostic pur-
poses. Only four CT-detected cancers (11%) could not be
assessed by PET because of inadequate blood sugar control or
claustrophobia.
Although TNM classification, with its continuous re-
fining,25 remains the fundamental instrument to assess lung
cancer prognosis, there is a growing demand for quantitative
and qualitative prediction of biologic aggressiveness across
anatomic TNM stages, to improve clinical management and
implement targeted therapies. This is particularly true for
FIGURE 1. Overall survival of lung cancer
patients by SUVmax values.
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screening detected cases, where it will become essential in
the future to discriminate indolent disease from potentially
metastatic cancer.
A systematic review on predictive and prognostic sig-
nificance of SUV at the time of lung cancer diagnosis,
showed in all the 11 included studies a significantly longer
survival for patients with low FDG uptake values,26 and SUV
emerged as an independent prognostic value at multivariate
Cox analysis in most of them. The review also pointed out the
difficulty to establish a consistent and reliable cutoff value for
SUV, given the heterogeneity of clinical series, variability in
the technique applied for the measurement of FDG uptake by
the various Institutions, and retrospective study design. More-
over, in the majority of reviewed papers, patient’s follow-up
was short and dichotomised comparison was based on median
or 2-year survival. A literature meta-analysis, based on 1474
patients from 13 studies (including those reported in the
above discussed review), calculated an overall hazard ratio of
2.27 (95% CI: 1.70–3.02) for higher maximum SUV value,
which remained substantially the same (HR 2.08, CI: 1.43–
3.04) after exclusion of the studies applying “best” cutoff
values.27 A recent study testing partial volume-corrected
SUVs failed to show the independent prognostic role of SUV
in resectble NSCLC: poorer survival of patients with SUV
more than 7 was in fact associated with tumor stage.28 This
study, however, used a different tracer (18F-FLT), which
evaluates cell proliferation rather than glucose metabolism,
and their conclusions may not be applicable to FDG uptake.
The intrinsic limitations of SUV are well described in
the literature and include its dependency on lesions dimen-
sions, location and motion, PET tomograph characteristics,
and time delay between FDG injection and uptake measure-
ment. Nonetheless, our study has unique clinical features: it is
the first screening trial to include PET in the diagnostic
protocol from the beginning of the trial, cancer patients are
unselected and nearly all cases occurring in the cohort during
the first 5 years were evaluable, all PET scans have been
performed using the same PET scanner and analyzed by the
same experienced observer (CL). As a matter of fact, a
previous report on the use of PET in a CT screening trial,24
only included 22 of 62 (35%) CT detected lung cancers.
Moreover, the follow-up was sufficiently extended
(median 74 months from diagnosis) to assess long-term
outcome in a reliable manner.
The choice of dividing patients in three groups corre-
sponds to a major biologic question in lung cancer screening:
to identify patients with potentially benign or indolent disease
on one side, and those with very aggressive disease, escaping
from early detection filter, on the opposite side. Cutoff values
selected to obtain the best discriminatory power are not at all
arbitrary: the SUV level of 2.5 has been considered a diag-
nostic threshold for malignancy, and the level of 8 represents
the largest gap in the distribution of values among remaining
patients. As a matter of fact, such threshold levels approached
random tertile distribution.
The resulting differences in long-term survival are quite
striking: SUVmax 2.5 define a homogeneous population of
small size (median diameter 11 mm, range 5–16), stage Ia
tumors, mostly adenocarcinomas, whose 100% survival sug-
gests an essentially nonmalignant behavior.28 Conversely, SUV
more than 8 defines a group of mostly advanced cancers (only
8% stage Ia), whose 20% survival is indicative of a highly
metastatic biologic profile, despite annual CT monitoring.
If on-going randomized trials will confirm the occur-
rence of significant overdiagnosis, as a consequence of chest
CT monitoring in heavy smokers, FDG-PET could be used to
reduce the risk of unnecessary treatments, such as radical
lobectomy for indolent disease, and implement targeted sys-
temic therapies for early metastatic lung cancer.
In conclusion, our results demonstrate that, by using the
present protocol, FDG-PET using SUV can predict long-term
survival of screening detected lung cancer, and metabolic
assessment of biologic behavior could be used in the future to
improve the clinical management of CT-detected lung cancer.
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